- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel treatment paradigms for metastatic uveal melanoma ; volume:29 ; number:12 ; day:1 ; month:12 ; year:2022 ; pages:1807-1808 ; date:12.2022
Cancer gene therapy ; 29, Heft 12 (1.12.2022), 1807-1808, 12.2022
- Urheber
-
Patel, Sapna P.
Katz, Steven C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41417-022-00558-y
- URN
-
urn:nbn:de:101:1-2023021721104040893940
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Patel, Sapna P.
- Katz, Steven C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Clinical determinants of long-term survival in metastatic uveal melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Clinical determinants of long-term survival in metastatic uveal melanoma
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma
Verification of EZH2 as a druggable target in metastatic uveal melanoma
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma
The immune cell landscape of metastatic uveal melanoma correlates with overall survival
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Clinical determinants of long-term survival in metastatic uveal melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Clinical determinants of long-term survival in metastatic uveal melanoma
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma
Verification of EZH2 as a druggable target in metastatic uveal melanoma
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma
The immune cell landscape of metastatic uveal melanoma correlates with overall survival
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Clinical determinants of long-term survival in metastatic uveal melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Clinical determinants of long-term survival in metastatic uveal melanoma
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma
Verification of EZH2 as a druggable target in metastatic uveal melanoma
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma